retatrutide weight loss clinical trials results 📈 PHASE 3 RESULTS: BY THE NUMBERS Let's break down what the actually showed: SURMOUNT-1 Trial (68 weeks): • Average loss: 24% of body weight • Participants Retatrutide Achieves Up to 30.3%

date last accessed)

FDA Requests Removal of Suicidal Behavior and Ideation Warning from Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) Medications

Cost-effectiveness of semaglutide in people with obesity and cardiovascular disease without diabetes

For instance, fresh research on non-invasive biomarkerseasy blood tests or scansmight make it far easier to monitor whether a patient is improving or if their risk of more severe illness remains high

Blood pressure drops 5 to 10 points systolic on average

The glucagon receptor adds a second accelerator to intestinal transit on top of the GLP-1 brake-then-release cycle